natgillin/translations-raw huggingface dataset:
In the larger AS study I with 315 patients, results showed statistically significant improvement of the signs and symptoms of ankylosing spondylitis in patients treated with Humira compared to placebo.
Rezultati većeg ispitivanja (AS I), u kojem je sudjelovalo 315 bolesnika, pokazali su statistički značajno poboljšanje znakova i simptoma ankilozantnog spondilitisa u bolesnika koji su primali lijek Humira u odnosu na bolesnike koji su primali placebo.
In the larger main study of patients with chronic phase CML, 90% of the patients responded to treatment, with blood levels of platelets and white blood cells returning to within predefined, normal values.
U većem glavnom ispitivanju provedenom na bolesnicima sa KML-om u kroničnoj fazi, 90% bolesnika odgovorilo je na terapiju, pri čemu su razine trombocita i bijelih krvnih stanica vraćene na prethodno definirane, normalne vrijednosti.
In the largest study, 67% of the patients with essential thrombocythaemia (628 out of 934), and 66% of those who could not tolerate or did not respond to other treatments (480 out of 725) had a complete response to Xagrid.
U najvećoj studiji, kod 67 % bolesnika s esencijalnom trombocitemijom (628 od 934) i 66 % onih koji nisu podnosili druge lijekove ili kod kojih je zabilježen izostanak odgovora na liječenje drugim lijekovima (480 od 725) zabilježen je potpuno uspješan odgovor na liječenje lijekom Xagrid.
In the largest study, which included 61 haemophilia patients with inhibitors, 84% of the 57 serious bleeds and 59% of the 38 surgical bleeds were controlled effectively with NovoSeven.
U najvećem ispitivanju, koje je uključivalo 61 bolesnika s hemofilijom s inhibitorima, 84 % od 57 ozbiljnih krvarenja te 59 % od 38 krvarenja kod operativnih zahvata učinkovito je kontrolirano zahvaljujući lijeku NovoSeven.
In the laser group 67 patients received rescue treatment with Eylea beginning at week 24 (Active Control/ Eylea 2mg group) which resulted in improvement of visual acuity by about 5 letters from week 24 to 52.
U skupini s laserom 67 bolesnika primilo je spasonosno liječenje lijekom Eylea početkom 24.tjedna (aktivna kontrola/skupina s lijekom Eylea 2 mg, što je rezultiralo poboljšanjem oštrine vida za otprilike 5 slova od 24. do 52. tjedna.
In the laser group 67 patients received rescue treatment with Eylea beginning at week 24 (Active Control/ Eylea 2mg group), which resulted in improvement of visual acuity by about 5 letters from week 24 to 52.
U skupini s laserom 67 bolesnika primilo je spasonosno liječenje lijekom Eylea početkom 24.tjedna (aktivna kontrola/skupina s lijekom Eylea 2 mg, što je rezultiralo poboljšanjem oštrine vida za otprilike 5 slova od 24. do 52. tjedna.
In the last study in patients who had never received treatment with DMARDs, almost 29% of patients (189 out of 655) treated with Cimzia in combination with methotrexate were in sustained remission after 52 weeks of treatment, compared with 15% (32 out of 213) of patients receiving placebo with methotrexate.
U posljednjem ispitivanju bolesnika koji nikad nisu primili terapiju DMARD-ima, u gotovo 29 % bolesnika (189 od 655) liječenih lijekom Cimzia u kombinaciji s metotreksatom postignuta je trajna remisija nakon 52 tjedna liječenja, u usporedbi s 15 % (32 od 213) bolesnika liječenih placebom u kombinaciji s metotreksatom.
In the lenalidomide/low dose dexamethasone group, 20 patients (9.1%) underwent at least one dose interruption compared to 65 patients (29.3%) in the lenalidomide/standard dose dexamethasone arm.
U skupini lenalidomid/niska doza deksametazona, 20 bolesnika (9,1%) imalo je bar jedan prekid doze u usporedbi sa 65 bolesnika (29,3%) u skupini lenalidomid/standardna doza deksametazona.
In the limited data available, there was no evidence of a marked ethnic difference in the PK of olaparib between Japanese and Caucasian patients.
Među ograničenim dostupnim podacima nisu pronađeni dokazi koji bi ukazivali na izraženu etnički uvjetovanu razliku u farmakokinetici olapariba između bolesnica japanskog podrijetla i bjelkinja.
In the limited number of co-infected subjects who did not achieve SVR and for whom population sequencing was performed, the prevalence of post-baseline RAVs was higher than that in mono- infected subjects in study SPRINT-2.
U malog broja ispitanika s istodobnom infekcijom HIV-om koji nisu postigli SVR i za koje je provedeno sekvenciranje populacije, prevalencija RAV-ova nakon početka ispitivanja bila je veća nego u ispitanika zaraženih samo HCV-om u ispitivanju SPRINT-2.
In the limited number of patients with prior exposure to non-liposomal irinotecan, no benefit of ONIVYDE has been demonstrated.
U ograničenog broja bolesnika koji su prethodno bili izloženi neliposomalnom irinotekanu, nije ustanovljena korist lijeka ONIVYDE.
In the liver hepatocyte hypertrophy or increased glycogen storage, increase in alanine aminotransferase (ALT) and alkaline phosphatase (ALP) were observed.
U jetri su primijećeni hipertrofija hepatocita ili pojačana pohrana glikogena, porast alanin- aminotransferaze (ALT) i alkalne fosfataze (ALP).
In the liver, 18 % of the injected activity is taken up 5 min after injection.
Jetra apsorbira 18% primijenjene aktivnosti 5 min nakon injekcije.
In the lomitapide clinical trials, one patient with HoFH developed markedly elevated aminotransferase (ALT 24x ULN, AST 13x ULN) within days of initiating the strong CYP3A4 inhibitor clarithromycin.
U kliničkim ispitivanjima lomitapida, jedan bolesnik s HoFH-om razvio je izrazito povišene aminotransferaze (ALT 24 x GGN, AST 13 x GGN) unutar nekoliko dana od uvođenja klaritromicina, snažnog inhibitora enzima CYP3A4.
In the long term extension part of this study (non controlled) the concomitant use of sildenafil and riociguat resulted in a high rate of discontinuation, predominately due to hypotension.
U dugoročnom produžetku ovog ispitivanja (nekontrolirano) istodobna primjena sildenafila i riocigvata dovela je do visoke stope prekida liječenja, pretežno zbog hipotenzije.
In the long term extension part of this study (non controlled) the concomitant use of sildenafil and riociguat resulted in a high rate of discontinuation, predominately due to hypotension.
U dugoročnom produžetku ovog ispitivanja (nekontrolirano) istodona primjena sildenafila i riocigvata dovela je do visoke stope prekida liječenja, pretežno zbog hipotenzije.
In the long term extension part of this study (non controlled) the concomitant use of sildenafil and riociguat resulted in a high rate of discontinuation, predominately due to hypotension.
U dugoročnom produžetku ovog ispitivanja (nekontroliranog) istodobna primjena sildenafila i riocigvata dovela je do visoke stope prekida liječenja, pretežno zbog hipotenzije.
In the long-term extension registry study for 16-23 year old women vaccinated with qHPV vaccine in the base study (n=1,984), no cases of HPV diseases (HPV types 6/11/16/18 related high grade CIN) were observed up to approximately 10 years.
U dugotrajnom produžetku ispitivanja na temelju registra u žena u dobi od 16 do 23 godine koje su cijepljene cjepivom qHPV u temeljnom ispitivanju (n=1984), u razdoblju do približno 10 godina nisu bili opaženi slučajevi bolesti povezanih s HPV-om (CIN visokog stupnja povezan s tipovima 6/11/16/18 HPV-a).
In the long-term extension study of Protocol 015, 1984 women 16-23 years old during vaccination with Gardasil in the base study were followed.
U dugotrajnom produžetku ispitivanja prema Protokolu 015, praćeno je 1984 žena cijepljenih cjepivom Gardasil koje su uključene u temeljno ispitivanje u dobi od 16 do 23 godine.
In the long-term extension study of Protocol 015, 1984 women 16-23 years old during vaccination with Silgard in the base study, were followed.
U dugotrajnom produžetku ispitivanja prema Protokolu 015, praćeno je 1984 žena cijepljenih cjepivom Silgard koje su uključene u temeljno ispitivanje u dobi od 16 do 23 godine.
In the long-term extension study of Protocol 019, 684 women 24-45 years old during vaccination with Gardasil in the base study were followed.
U dugotrajnom produžetku ispitivanja prema Protokolu 019, praćeno je 684 žena cijepljenih cjepivom Gardasil koje su uključene u temeljno ispitivanje u dobi od 24 do 45 godina.
In the long-term extension study of Protocol 019, 684 women 24-45 years old during vaccination with Silgard in the base study, were followed.
U dugotrajnom produžetku ispitivanja prema Protokolu 019, praćeno je 684 žena cijepljenih cjepivom Silgard koje su uključene u temeljno ispitivanje u dobi od 24 do 45 godina.
In the long-term extension study of Protocol 020, 918 men 16-26 years old during vaccination with Gardasil in the base study were followed.
U dugotrajnom produžetku ispitivanja prema Protokolu 020, praćeno je 918 muškaraca cijepljenih cjepivom Gardasil koji su uključeni u temeljno ispitivanje u dobi od 16 do 26 godina.
In the long-term extension study of Protocol 020, 918 men 16-26 years old during vaccination with Silgard in the base study, were followed.
U dugotrajnom produžetku ispitivanja prema Protokolu 020, praćeno je 918 muškaraca cijepljenih cjepivom Silgard koji su uključeni u temeljno ispitivanje u dobi od 16 do 26 godina.
In the long-term extension trial (50 weeks), a total of 34.8 % of subjects experienced clinically significant weight increase (i.e., ≥ 7 % increase in body weight at endpoint).
U dugoročnom nastavku ispitivanja (50 tjedana), u ukupno 34,8% ispitanika došlo je do porasta tjelesne težine koji je bio klinički značajan (tj. ≥ 7%-tni porast tjelesne težine na kraju ispitivanja).
In the long-term open-label extension phase of these controlled studies, in which patients received silodosin for up to 1 year, the symptom improvement induced by silodosin at week 12 of treatment was maintained over 1 year.
U fazi dugotrajnog produžetka otvorenog tipa ovih kontroliranih ispitivanja u kojoj su bolesnici primali silodozin u razdoblju do 1 godine, poboljšanje simptoma izazvano silodozinom do 12. tjedna liječenja održalo se tijekom 1 godine.
In the long-term outcome trial, a total of 2072 patients received 30 mg tolvaptan with standard of care (SC) and 2061 received placebo with SC.
U ispitivanju dugoročnih ishoda, ukupno 2072 bolesnika primilo je 30 mg tolvaptana uz standardnu njegu (SNJ) a 2061 primilo je placebo uz standardnu njegu.
In the long-term studies, Abilify was more effective than placebo, and as effective as haloperidol, after up to a year of treatment.
U dugoročnim je ispitivanjima Abilify bio djelotvorniji od placeba te jednako djelotvoran kao i haloperidol, do godine dana liječenja.
In the long-term study with Esmya, 49% of women receiving 5 mg Esmya (95 out of the 195 women who were assessed) had no more than one day of spotting within a 35-day interval after each of the 4 treatment courses, and 70% had no more than one day of spotting within a 35-day interval at the end of treatment course 4.
U dugoročnom ispitivanju lijeka Esmya, 49 % žena koje su primile 5 mg lijeka Esmya (95 od 195 žena koje su ocijenjene) imalo je samo jedan dan vrlo laganog krvarenja unutar intervala od 35 dana nakon svake od četiri serije terapije, a 70 % ih je imalo samo jedan dan vrlo laganog krvarenja unutar intervala od 35 dana na kraju 4. serije terapije.
In the LTPS, there were 263 evaluable zoster cases reported among 261 patients [10.3/1000 person- years].
U podispitivanju LTPS moglo se procijeniti 263 slučaja herpes zostera prijavljenih u 261 bolesnika [10,3/1000 osoba-godina].
In the lung cancer study in patients with activating EGFR mutations, patients on Avastin plus erlotinib had progression-free survival of 16.0 months on average compared with 9.7 months in patients given erlotinib alone.
U ispitivanju raka pluća u bolesnika s aktivirajućim EGFR mutacijama, u bolesnika koji su primali Avastin s erlotinibom preživljenje bez progresije bolesti iznosilo je u prosjeku 16,0 mjeseci u usporedbi s 9,7 mjeseci u bolesnika koji su primali samo erlotinib.
In the lung/gut neuroendocrine tumour study, patients who took Afinitor lived for an average of 11 months without the disease getting worse, compared with around 4 months for patients given placebo.
U ispitivanju bolesnika s neuroendokrinim tumorom s primarnim sijelom u plućima ili probavnom sustavu, bolesnici koji su uzimali lijek Afinitor živjeli su prosječno 11 mjeseci bez pogoršanja bolesti u usporedbi s otprilike 4 mjeseca u slučaju bolesnika koji su uzimali placebo.
In the lyophilisate: urea, sodium chloride, polysorbate 20, sodium dihydrogen phosphate, disodium hydrogen phospate, calcium chloride, glycine, L-Leucine, L-Isoleucine, L-Threonine, L-Glutamic acid, and L-Phenylalanine.
U liofilizatu: urea, natrijev klorid, polisorbat 20, natrijev dihidrogenfosfat, natrijev hidrogenfosfat, kalcijev klorid, glicin, L-leucin, L-izoleucin, L-treonin, L-glutamatna kiselina, L-fenilalanin.
In the main clinical efficacy studies, lurasidone was administered at doses of 37-148 mg lurasidone (equivalent to 40-160 mg lurasidone hydrochloride).
U glavnim kliničkim ispitivanjima djelotvornosti, lurasidon je primjenjivan u dozama od 37-148 mg lurasidona (što odgovara 40-160 mg lurasidonklorida).
In the main field study, dogs of various breeds, age groups, gender and different weights were treated with either Certifect or a similar ‘spot-on’ medicine containing fipronil and (S)-methoprene.
U glavnom terenskom ispitivanju, psi različitih pasmina, dobnih skupina, spolova i različitih težina liječeni su VMP-om Certifect ili sličnom otopinom za nakapavanje na kožu koja sadrži fipronil i (S)-metopren.
In the main study in axial spondyloarthritis, 58% of patients receiving Cimzia 200 mg every 2 weeks and 64% of patients receiving Cimzia 400 mg every 4 weeks achieved at least a 20% reduction compared with 38% of patients receiving placebo.
U glavnom ispitivanju aksijalnog spondiloartritisa, u 58 % bolesnika koji su primali lijek Cimzia od 200 mg svaka 2 tjedna i u 64 % bolesnika koji su primali lijek Cimzia od 400 mg svaka 4 tjedna postignuto je najmanje 20 %-tno smanjenje u usporedbi s 38 % bolesnika koji su primali placebo.
In the main study in PNH, 49% of the adult patients receiving Soliris had stable haemoglobin levels (21 out of 43), and, on average, they did not need any transfusions of red blood cells.
U glavnom ispitivanju bolesti PNH-a, 49 % odraslih bolesnika koji su primili Soliris imalo je stabilne razine hemoglobina (21 od 43) te im, u prosjeku, nisu bile potrebne transfuzije crvenih krvnih stanica.
In the main study, Jevtana prolonged overall survival compared with the comparator medicine mitoxantrone.
U glavnom ispitivanju, lijek Jevtana produljio je ukupno preživljenje u usporedbi s komparatorskim lijekom mitoksatronom.
In the majority of cases, vomiting was transient and mild and did not require symptomatic treatment.
U većini slučajeva, povraćanje je bilo prolazno i blago te nije zahtijevalo simptomatsku terapiju.
In the majority of patients the pain was related to the patients’ underlying cancer or metastases or pre-existing or concomitant conditions.
U većine je bolesnika bol bila povezana s podležećim rakom ili metastazama ili otprije postojećim ili popratnim bolestima.
In the majority of patients who experienced flushing, it was mild or moderate in severity.
U većine bolesnika kod kojih se pojavilo crvenilo uz osjećaj vrućine, ono je bilo blago ili umjereno.
In the majority of patients who have not yet had an operation for cataract, a clouding of the eye's natural lens (a cataract) may occur after repeated treatment with OZURDEX.
U većine bolesnika koji još nisu podvrgnuti operaciji mrene, zamućenje prirodne očne leće (mrena) može nastupiti nakon ponovljenih tretmana lijekom OZURDEX.
In the majority of patients with urea cycle disorders or haemoglobinopathies receiving various doses of phenylbutyrate (300 - 650 mg/kg/day up to 20 g/day) no plasma level of phenylacetate could be detected after overnight fasting.
U većine bolesnika s poremećajem ciklusa ureje ili hemoglobinopatijom koji su primali različite doze fenilbutirata (300 – 650 mg/kg/dan do 20 g/dan) nakon noćnog posta nije otkrivena prisutnost fenilacetata u plazmi.
In the majority of patients, immunogenicity occurred early in treatment and was transient resolving by 2 to 4 months.
U većine je bolesnika imunogenost nastupila u ranoj fazi liječenja, no bila je prolazna i povukla se nakon 2 – 4 mjeseca.
In the majority of these cases, MabThera was administered with chemotherapy.
U većini tih slučajeva MabThera je primijenjena u kombinaciji s kemoterapijom.
In the majority of these patients the elevations were generally mild, and remained below two times the upper limit of normal range
U većine ovih bolesnika povećanja su bila općenito blaga i ostala su niža od dvostrukog povećanja gornje granice normalnog raspona.
In the male and female rat, following intravenous administration, Lutetium (177Lu) chloride is rapidly cleared from the blood: at 5 min post injection, only 1.52% of the injected activity (%ID) is found in blood (corresponding to 0.08%ID/g) and no activity above background levels remains 1 hour post dose.
U mužjaka i ženki štakora lutecijev (177Lu) klorid brzo se eliminira iz krvi nakon intravenske primjene: pet minuta nakon injekcije, u krvi postoji samo 1,52 % ubrizgane aktivnosti (%ID) (što odgovara vrijednosti od 0,08 %ID/g), dok jedan sat nakon ubrizgavanja doze u krvi nema nikakve aktivnosti iznad pozadinske razine.
In the male dog, after one year of dosing, reversible bile plugs in canaliculi were observed at exposures greater than 1.9 fold the human exposure.
U mužjaka pasa nakon godine dana doziranja primijećeni su reverzibilni čepovi žuči u kanalićima pri ekspozicijama 1,9 puta većim od ekspozicije u ljudi.
in the maximum PR interval
maksimalnog PR-intervala u
In the MCL Clinical Trial, a Phase 3 clinical trial for mantle cell lymphoma, 11% of patients reported hyperglycaemia as an adverse event.
U MCL kliničkom ispitivanju - kliničkom ispitivanju faze III limfoma plaštenih stanica, 11% bolesnika prijavilo je hiperglikemiju kao štetni događaj.
In the MCL Clinical Trial, hyperlipaemia was reported as an adverse event in 9.3% of patients.
U MCL kliničkom ispitivanju, hiperlipemija je bila zabilježena kao štetni događaj u 9,3% bolesnika.
In the MCL Clinical Trial, there was no difference in efficacy in patients with respect to age, sex, race, geographic region, or baseline disease characteristics.
U MCL kliničkom ispitivanju nije bilo razlike u djelotvornosti s obzirom na dob, spol, rasu, geografsku regiju ili početne značajke bolesti.
In the meta-analysis, the overall mean difference to placebo across the studies was statistically significant: -2.3 points (p = 0.007), -3.6 points (p <0.001), and -4.6 points (p <0.001) for the 5, 10, and 20 mg/day doses, respectively; the 15mg/day dose did not separate from placebo in the meta-analysis, but the mean difference to placebo was -2.6 points.
U meta analizama, ukupna srednja razlika od placeba kroz ispitivanja je bila statistički značajna: -2,3 boda (p=0,007), -3,6 bodova (p < 0,001 i -4,6 bodova (p < 0,001) za doze od 5, 10 odnosno 20 mg dnevno; doza od 15 mg dnevno se nije udaljila od placeba u meta analizi, ali je razlika od placeba bila -2,6 bodova.
In the mid-gut of susceptible insect species, the insect’s enzymes remove the carbomethoxy group from parent indoxacarb, and convert it into its biologically active form.
U srednjem crijevu osjetljivih vrsta insekata, enzimi uklanjaju karbometoksi skupinu od indoksakarba i na taj način ga pretvaraju u biološki aktivni oblik.
In the mid-gut of susceptible insect species, the insect’s enzymes remove the carbomethoxy group from parent indoxacarb, and convert it into its biologically active form.
U srednjem crijevu osjetljivog insekta, enzimi uklanjaju karbometoksi grupu indoksikarb molekule i pretvaraju je u biološki aktivni oblik.
In the middle of the cycle (Week Two/Day 8 or Week Three/Day 15) for one or two days (up to 48 hours): The user should apply a new EVRA transdermal patch immediately.
U sredini ciklusa (2. tjedan/8. dan ili 3. tjedan/15. dan) jedan ili dva dana (do 48 sati): žena treba odmah primijeniti novi EVRA transdermalni flaster.
In the modified ITT population, the benefit of the vaccine with respect to the overall incidence of CIN 2/3 or AIS (caused by any HPV type) and of genital warts was much lower, with a reduction of 18.4% (95% CI: 7.0, 28.4) and 62.5% (95% CI: 54.0, 69.5), respectively, as Silgard does not impact the course of infections or disease that are present at vaccination onset.
U modificiranoj ITT populaciji, korist od cijepljenja s obzirom na ukupnu incidenciju CIN-a 2/3 odnosno AIS-a (uzrokovanih bilo kojim tipom HPV-a) te na genitalne bradavice, bila je znatno manja, sa smanjenjem od 18,4% (95% CI: 7,0; 28,4) za CIN 2/3 i AIS odnosno 62,5% (95% CI: 54,0; 69,5) za genitalne bradavice, budući da Silgard ne utječe na tijek infekcije odnosno bolesti koje su bile prisutne na početku cijepljenja.
In the morning, take 600 milligram PREZISTA together with 100 milligram ritonavir.
Ujutro uzmite uzmite 600 miligrama lijeka PREZISTA zajedno sa 100 miligrama ritonavira.
In the morning, take one 200 milligram INTELENCE tablet, following a meal.
Ujutro, nakon obroka uzmite jednu tabletu INTELENCEa od 200 miligrama.
In the morning, take one 600 milligram PREZISTA tablet together with 100 milligram ritonavir.
Ujutro uzmite jednu tabletu lijeka PREZISTA od 600 miligrama zajedno sa 100 miligrama ritonavira.
In the morning, take two 100 milligram INTELENCE tablets, following a meal.
Ujutro, nakon obroka uzmite dvije tablete INTELENCEa od 100 miligrama.
In the morning, take two 300 milligram PREZISTA tablets together with 100 milligram ritonavir.
Ujutro uzmite dvije tablete lijeka PREZISTA od 300 miligrama zajedno sa 100 miligrama ritonavira.
In the most extreme case of overdose, the patient survived the oral intake of a total of 2,000 mg memantine with effects on the central nervous system (coma for 10days, and later diplopia and agitation).
U ekstremnom slučaju predoziranja bolesnik je preživio peroralno uzimanje ukupne količine od 2000 mg memantina s učincima na središnji živčani sustav (koma tijekom 10 dana, a nakon toga diplopija i agitacija).
In the most extreme case of overdose, the patient survived the oral intake of a total of 2000mg memantine with effects on the central nervous system (coma for 10 days, and later diplopia and agitation).
U najekstremnijem slučaju predoziranja bolesnik je preživio peroralno uzimanje ukupne količine od 2000 mg memantina s učincima na središnji živčani sustav (koma tijekom 10 dana, a nakon toga diplopija i agitacija).
In the most extreme case of overdose, the patient survived the oral intake of a total of 2000mg memantine with effects on the central nervous system (coma for 10 days, and later diplopia and agitation).
U najekstremnijem slučaju predoziranja, bolesnik je preživio peroralno uzimanje ukupne količine od 2000 mg memantina s učincima na središnji živčani sustav (koma tijekom 10 dana, a nakon toga diplopija i agitacija).
In the mouse, the overall incidence of major abnormalities and the incidence for major skeletal abnormalities were increased.
Kod miševa je povećana sveukupna incidencija velikih abnormalnosti te incidencija velikih abnormalnosti skeleta.
In the MRI cohort 36% of patients entering the study had Gd+ lesions at baseline (mean number of Gd+ lesions 1.4).
U MR kohorti 36% bolesnika koji su ušli u ispitivanje imali su Gd + lezije na početku (srednja vrijednost broja Gd + lezija 1,4).
In the MRI cohort 45% of patients entering the study had Gd+ lesions at baseline (mean number of Gd+ lesions 2.4).
U MR kohorti 45% bolesnika koji su ušli u ispitvanje imali su Gd + lezije na početku (srednja vrijednost broja Gd + lezija 2,4).